Tenaya Therapeutics, Inc. (TNYA) Current Ratio
- Current ratio · latest quarter: Value 4.52×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.52× | Current assets / current liabilities. $86.01M ÷ $19.02M ≈ 4.52× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 86.01M USD | Assets, Current |
| Current obligations | 19.02M USD | Liabilities, Current |
| Cash and equivalents | 78.08M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 371.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 2.90M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $86.01M | $19.02M | $78.08M | (m) | $371.00K | (m) | $2.90M | (m) | 4.52× |
| 2026-03-31 | $96.56M | $16.78M | $80.89M | (m) | $10.63M | (m) | $1.91M | (m) | 5.75× |
| 2025-12-31 | $105.59M | $15.44M | $100.55M | (m) | (m) | (m) | $3.58M | (m) | 6.84× |
| 2025-09-30 | $61.24M | $13.21M | $56.31M | (m) | (m) | (m) | $2.84M | (m) | 4.64× |
| 2025-06-30 | $75.88M | $12.65M | $62.67M | (m) | (m) | (m) | $3.30M | (m) | 6.00× |
| 2025-03-31 | $94.48M | $14.15M | $53.77M | (m) | (m) | (m) | $5.06M | (m) | 6.68× |
| 2024-12-31 | $67.38M | $15.97M | $4.32M | (m) | (m) | (m) | $5.16M | (m) | 4.22× |
| 2024-09-30 | $85.33M | $16.18M | $8.23M | (m) | (m) | (m) | $5.84M | (m) | 5.27× |
| 2024-06-30 | $105.03M | $16.71M | $58.13M | (m) | (m) | (m) | $4.32M | (m) | 6.28× |
| 2024-03-31 | $128.70M | $19.16M | $59.30M | (m) | (m) | (m) | $6.66M | (m) | 6.72× |
| 2023-12-31 | $111.58M | $22.73M | $45.68M | (m) | (m) | (m) | $5.63M | (m) | 4.91× |
| 2023-09-30 | $126.83M | $19.38M | $82.15M | (m) | (m) | (m) | $5.90M | (m) | 6.55× |
| 2023-06-30 | $138.91M | $20.92M | $75.56M | (m) | (m) | (m) | $8.48M | (m) | 6.64× |
| 2023-03-31 | $154.63M | $19.30M | $72.54M | (m) | (m) | (m) | $7.43M | (m) | 8.01× |
| 2022-12-31 | $193.75M | $24.25M | $95.27M | (m) | (m) | (m) | $9.58M | (m) | 7.99× |
| 2022-09-30 | $157.07M | $17.72M | $34.49M | $114.96M | (m) | (m) | $5.31M | (m) | 8.87× |
| 2022-06-30 | $185.69M | $18.74M | $31.01M | $149.91M | (m) | (m) | $5.35M | (m) | 9.91× |
| 2022-03-31 | $213.78M | $19.09M | $25.97M | $184.48M | (m) | (m) | $8.89M | (m) | 11.20× |
| 2021-12-31 | $255.36M | $21.77M | $38.13M | (m) | (m) | (m) | $10.72M | (m) | 11.73× |
| 2021-09-30 | $284.82M | $13.69M | $117.08M | $163.39M | (m) | (m) | $6.17M | (m) | 20.80× |
| 2021-06-30 | $113.22M | $9.80M | $111.89M | (m) | (m) | (m) | $5.02M | (m) | 11.55× |
| 2020-12-31 | $129.96M | $5.04M | $128.53M | (m) | (m) | (m) | $1.02M | (m) | 25.78× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |